ClinicalTrials.gg
Active, not recruitingNCT06724614Updated Nov 6, 2025

Efficacy and Safety of VDPHL01 in Males With AGA

A Phase 2/3 interventional study of VDPHL01 and Placebo in Androgenetic Alopecia, AGA and Male Pattern Baldness, sponsored by Veradermics, Inc.. Active, not recruiting at 44 sites in United States. Open to male participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-11-06.

Sponsored by Veradermics, Inc. · Phase 2/3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Feb 2026, 9 months ago, but the record still lists the study as active, not recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
480
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 216 studies in Alopecia with a site in United States — 43 open to participants now, 63 under way, 6 of them phase 3. Alopecia · United States.

Planned enrollment
11th of 203
480 · median 40
Started
2024
with 19 others
Phase 2/3
3 of 216
1 open now
Primary completion
2026-02
later than 13 of 62 live
Registered
181st of 216
by date

Among the 216 studies in Alopecia with a site in United States, this one is the 11th largest by planned enrollment of the 203 interventional ones that give a count, is one of 20 that started in 2024, is one of 3 in phase 2/3, reaches primary completion later than 13 of the 62 other live ones, and was the 181st registered.

Alopecia

512 studies on the registry are indexed under Alopecia; 129 are open to participants now.

Browse Alopecia studies →

Open to participants now

43 of the 216 studies in Alopecia with a site in United States are open now. Recruiting first, the newest first:

38 more — sign in →

All 43 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 75 Alopecia studies recruiting now, 25 (33%) set no upper age limit and 46 (61%) stop at 75 or younger; 9 take children under 18; 24 take healthy volunteers.

This study: 18 Years to 65 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 216 studies in Alopecia with a site in United States, or all of them as a file.
02

Study summary

This study will evaluate the safety and efficacy of VDPHL01 in male subjects with Androgenetic Alopecia (AGA).

AGA (or male pattern baldness) is a genetic disorder caused by an excessive (too much) hair follicle response to androgens (hormone) that causes hair loss. VDPHL01 8.5 mg Tablet is an investigational oral drug to treat male pattern baldness.

This multi-center, double blind, study will last about 13 months and includes 11 study visits (screening, baseline (day 1), week 2, month 1, month 2, month 4, month 6, month 8, month 10, month 12, month 13).

The first 7 visits will be part of the placebo-controlled period. The next 3 visits will be part of the treatment extension phase. All subjects will receive active drug in the treatment extension phase.

03

Conditions studied

  • Androgenetic Alopecia
  • AGA
  • Male Pattern Baldness

Browse trials for

Keywords

  • Hair Loss
  • Male Hair Loss
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject is male aged 18-65 years old;
  • Subject has a clinical diagnosis of mild to moderate AGA;
  • Subject is in good general health and has normal renal and hepatic function;
  • Subject is willing to maintain at least 1/4 inch length hair during the study with the same hairstyle, hair length, and hair color throughout the study; maintain consistent use of general hair care products and regimen through the entire study;
  • Subject is willing and able to administer the test article as directed read, understand, and complete required questionnaires in English;
  • Subject is willing and able to swallow study drug whole;
  • Subject agrees to have a micro dot tattoo placed on their scalp;
  • Subject agrees to have this area photographed at study visits as indicated in the protocol.

Exclusion criteria

Exclusion Criteria:

  • Subject has uncontrolled blood pressure or orthostatic hypotension;
  • Subject has symptoms or history of certain heart or thyroid conditions;
  • Subject has a history of or active hair loss due to conditions/diseases other than AGA;
  • Subject has a current or recent history of dietary or weight changes, including use of GLP-1 agonists;
  • Subject has been diagnosed with COVID-19 within 16 weeks of screening;
  • Subject has had previous radiation of the scalp;
  • Use of any of the following treatments within the indicated before screening:

    • Subject has used hormone replacement therapy or hormonal modulators within 6 months prior to screening
    • Subject has used oral treatments for hair growth or that can affect hair growth, including systemic retinoids, within 6 months of screening
    • Subject has used systemic calcium channel blockers or beta blockers within 12 weeks prior to screening
    • Subject has used systemic cimetidine, ketoconazole, diazoxide, or (including intramuscular, intraarticular, and intralesional injections) within 12 weeks prior to screening
    • Subject has had any scalp procedures, including surgical, laser, light or energy treatments, micro-needling, injections, rich plasma within 6 months prior to screening
    • Subject has used any topical scalp treatments for hair growth within 12 weeks prior to screening
  • Subject has used any other therapy with any medication either topical or oral that might, in the investigator's opinion, interfere with the study;
  • Subject has any other condition that, in the investigator's opinion, interfere with the study
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
480 participants (estimated)

Study arms

  • Experimental
    VDHPL01 BID

    VDPHL01 will be taken orally twice a day, once in the AM and once in the PM.

    Drug: VDPHL01

  • Experimental
    VDPHL01 QD and Placebo QD

    Placebo will be taken orally once a day in the AM or PM. VDPHL01 will be taken orally once a day in the AM or PM.

    Drug: VDPHL01

  • Placebo comparator
    Placebo BID with treatment extension to VDPHL01 BID

    Placebo will be taken orally twice a day, once in the AM and once in the PM for the first 6 months of the study. After month 6, VDPHL01 will be taken orally twice a day, once in the AM and once in the PM.

    Drug: Placebo

  • Placebo comparator
    Placebo BID with treatment extension to VDPHL01 QD and Placebo QD

    Placebo will be taken orally twice a day, once in the AM and once in the PM for the first 6 months of the study. After month 6, placebo will be taken orally once a day in the AM or PM. VDPHL01 will be taken orally once a day in the AM or PM.

    Drug: Placebo

Interventions

  • VDPHL01 Extended Release (ER) Tablet

  • DrugPlacebo

    Placebo

06

What researchers measure

Primary outcomes

  1. Changes in non-vellus Target Area Hair Counts (TAHC)

    Change from baseline in non-vellus TAHC using digital image analysis at Month 6.

    Time frame: Month 6

  2. Subjects Evaluation of Treatment Benefit

    Subjects will rate their treatment benefit by responding to a hair assessment scale. The proportion of subjects by each response category will be reported at Month 6.

    Time frame: Month 6

07

Study locations

44 sites
  • Site 36
    Birmingham, Alabama 35203, United States
  • Site 28
    Phoenix, Arizona 85018, United States
  • Site 30
    Fort Smith, Arkansas 72916, United States
  • Site 35
    Rogers, Arkansas 72758, United States
  • Site 07
    Fountain Valley, California 92728, United States
  • Site 02
    Fremont, California 94538, United States
  • Site 34
    Sherman Oaks, California 91403, United States
  • Site 21
    Vista, California 92083, United States
  • Site 05
    Castle Rock, Colorado 80109, United States
  • Site 24
    Englewood, Colorado 80111, United States
  • Site 17
    Aventura, Florida 33180, United States
  • Site 25
    Brandon, Florida 33511, United States
  • Site 42
    Hollywood, Florida 33021, United States
  • Site 03
    Tampa, Florida 33613, United States
  • Site 43
    Atlanta, Georgia 30329, United States
  • Site 31
    Boise, Idaho 83704, United States
  • Site 23
    Rolling Meadows, Illinois 60008, United States
  • Site 15
    Indianapolis, Indiana 46250, United States
  • Site 32
    New Albany, Indiana 47150, United States
  • Site 27
    West Lafayette, Indiana 47906, United States
  • Site 41
    Baton Rouge, Louisiana 70809, United States
  • Site 13
    Covington, Louisiana 70433, United States
  • Site 12
    Metairie, Louisiana 70006, United States
  • Site 22
    Brighton, Massachusetts 02135, United States
  • Site 26
    Clarkston, Michigan 48346, United States
  • Site 06
    New Brighton, Minnesota 55112, United States
  • Site 18
    Hackensack, New Jersey 07601, United States
  • Site 37
    Kew Gardens, New York 11415, United States
  • Site 38
    New York, New York 10075, United States
  • Site 39
    Boardman, Ohio 44512, United States
  • Site 11
    Columbus, Ohio 43215, United States
  • Site 08
    Broomall, Pennsylvania 19073, United States
  • Site 10
    Plymouth Meeting, Pennsylvania 19462, United States
  • Site 20
    Greensville, South Carolina 29615, United States
  • Site 09
    Knoxville, Tennessee 37909, United States
  • Site 16
    Murfreesboro, Tennessee 37130, United States
  • Site 04
    Nashville, Tennessee 37215, United States
  • Site 40
    Bellaire, Texas 77401, United States
  • Site 44
    Dallas, Texas 75231, United States
  • Site 14
    Houston, Texas 77056, United States
  • Site 19
    West Jordan, Utah 84095, United States
  • Site 29
    Lynchburg, Virginia 24501, United States
  • Site 33
    Seattle, Washington 98168, United States
  • Site 01
    Spokane, Washington 99202, United States
08

References and documents

Related links

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2024 (actual). Primary completion is estimated for Feb 2026, 15 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 4, 2024
First posted
Dec 9, 2024
StartActual
Nov 6, 2024
Primary completionEst.
Feb 2026
CompletionEst.
Sep 2026
Last update
Nov 6, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 6, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06724614
Lead sponsor
Veradermics, Inc.
Responsible party
Sponsor
First posted
Dec 9, 2024
Start date
Nov 6, 2024
Primary completion
Feb 2026 (estimated)
Completion
Sep 2026 (estimated)
Last update
Nov 6, 2025

Study contacts

Reid Waldman, M.D.
study chair · Veradermics, Inc.
Timothy Durso, M.D.
study chair · Veradermics, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: VDPHL01

Start the discussion